Loss of protective sensation is the single strongest predictor of diabetic foot ulceration, and most of it is attributed to distal symmetrical polyneuropathy driven by chronic hyperglycaemia. But not every insensate foot in a person with diabetes is purely glycaemic in origin. Vitamin B12 deficiency produces a clinically similar sensory neuropathy, and it is substantially more common in people taking metformin, the first-line oral agent for type 2 diabetes. Unlike glycaemic neuropathy, B12 deficiency is cheap to detect and treatable, which makes it worth understanding precisely.
How Metformin Affects Vitamin B12 Status
Vitamin B12 (cobalamin) is absorbed in the terminal ileum, where the intrinsic factor–B12 complex binds the cubam receptor in a calcium-dependent manner; metformin is thought to interfere with this step. Because the liver stores several years’ worth of B12, depletion is slow, which is why duration and daily dose matter more than simply being on the drug. B12 is a cofactor for enzymes central to DNA synthesis and myelin maintenance, so deficiency produces progressive axonal demyelination, peripheral neuropathy, and haematological changes including macrocytic anaemia (Bell, Diabetes, Obesity & Metabolism, 2022; Infante et al., World Journal of Diabetes, 2021). Proton pump inhibitor use, bariatric surgery, older age, and increased red cell turnover all accelerate depletion of hepatic stores.
How Common Is the Deficiency?
The association is consistent across the literature. A meta-analysis of 31 studies by Yang and colleagues found that patients with diabetes taking metformin had roughly double the risk of vitamin B12 deficiency compared with those not taking it (RR 2.09; 95% CI 1.49–2.93) and serum B12 concentrations about 64 pmol/L lower, with the effect depending on both dose and treatment duration (Journal of Diabetes, 2019). An earlier systematic review by Chapman and colleagues reported a comparable mean reduction of 57 pmol/L (Diabetes & Metabolism, 2016). A 2022 meta-analysis of 17 studies found deficiency in 23.2% of metformin users versus 17.4% of non-users (OR 2.95), again with dose and duration as the significant modifiers (Kakarlapudi et al., Cureus).
Dose thresholds are becoming clearer. In a multicentre cross-sectional study of 1,027 Chinese patients taking at least 1,000 mg/day for a year or more, frank deficiency was uncommon (2.15%) but borderline deficiency was not (13.66%). Patients on 1,500 mg/day or more had significantly higher rates of borderline deficiency than those on lower doses (16.8% vs 9.9%) (Gao et al., Journal of Diabetes, 2023).
Does Lower B12 Translate Into More Neuropathy?
This is where the evidence becomes genuinely mixed, and clinicians should be careful not to overstate it. Yang’s meta-analysis found no statistically significant association between metformin use and the prevalence of either anaemia or neuropathy, despite the clear effect on B12 levels. The Gao cross-sectional study likewise found that higher daily dosing drove deficiency without a corresponding increase in peripheral neuropathy.
Cohort data point the other way. In a Beijing claims-based cohort of 49,705 patients with newly diagnosed type 2 diabetes followed for a median 6.4 years, metformin-treated patients had an 84% higher rate of admission for diabetic peripheral neuropathy (HR 1.84; 95% CI 1.62–2.10), with a dose–response gradient. Notably, among patients already taking vitamin B12 at baseline, no excess risk was seen (Yang et al., Frontiers in Endocrinology, 2023). Prospective studies summarised by Bell also report higher frequencies of both distal symmetrical and cardiac autonomic neuropathy in metformin users.
The reasonable interpretation is that metformin reliably lowers B12, that low B12 is a biologically coherent contributor to neuropathy in a subset of patients, and that the population-level signal remains inconsistent across study designs.
Screening, Diagnosis, and Response to Treatment
American Diabetes Association Standards of Care advise considering periodic assessment of vitamin B12 in people on long-term metformin, particularly at doses of 1,500 mg/day or higher, after four to five years of therapy, and when anaemia, peripheral neuropathy, or chronic kidney disease is present. No screening interval has been formally established. Where serum B12 is borderline rather than frankly low, methylmalonic acid and homocysteine can identify functional deficiency earlier (Yazidi et al., Korean Journal of Family Medicine, 2024).
Supplementation does raise B12 levels reliably; its neurological benefit is less certain. A systematic review of seven trials (506 participants) found consistent increases in serum B12 but inconsistent effects on neuropathy symptoms, with two trials showing improvement and one showing none (Pratama et al., Diabetes & Metabolic Syndrome, 2022). The strongest single trial is a 12-month double-blind randomised study of 90 metformin-treated patients with neuropathy and B12 below 400 pmol/L: 1,000 µg/day of oral methylcobalamin improved vibration perception threshold, sural nerve conduction velocity and action potential amplitude, pain scores, and quality of life, while several of these measures deteriorated in the placebo group (Didangelos et al., Nutrients, 2021). Bell’s review offers a more conservative framing: with adequate replacement, objective findings tend to stabilise rather than reverse.
Clinical Summary
Metformin lowers vitamin B12 in a dose- and duration-dependent way, roughly doubling the risk of deficiency. Whether that deficiency independently worsens neuropathy remains contested, but it is a potentially modifiable contributor in a population where sensory loss carries direct consequences for the foot. Checking B12 in a long-term, higher-dose metformin user with sensory symptoms costs little, and where deficiency is confirmed, replacement may at minimum halt progression — removing one treatable cause from the differential alongside, not instead of, glycaemic management and structured foot risk assessment.
References
- Yang W, Cai X, Wu H, Ji L. Associations between metformin use and vitamin B12 levels, anemia, and neuropathy in patients with diabetes: a meta-analysis. Journal of Diabetes. 2019;11(9):729–743. doi:10.1111/1753-0407.12900
- Chapman LE, Darling AL, Brown JE. Association between metformin and vitamin B12 deficiency in patients with type 2 diabetes: a systematic review and meta-analysis. Diabetes & Metabolism. 2016;42(5):316–327. doi:10.1016/j.diabet.2016.03.008
- Gao L, Ran X, Liu X, et al. The effects of daily dose and treatment duration of metformin on the prevalence of vitamin B12 deficiency and peripheral neuropathy in Chinese patients with type 2 diabetes mellitus: a multicenter cross-sectional study. Journal of Diabetes. 2023;15(9):765–776. doi:10.1111/1753-0407.13428
- Yang R, Yu H, Wu J, et al. Metformin treatment and risk of diabetic peripheral neuropathy in patients with type 2 diabetes mellitus in Beijing, China. Frontiers in Endocrinology. 2023;14:1082720. doi:10.3389/fendo.2023.1082720
- Didangelos T, Karlafti E, Kotzakioulafi E, et al. Vitamin B12 supplementation in diabetic neuropathy: a 1-year, randomized, double-blind, placebo-controlled trial. Nutrients. 2021;13(2):395. doi:10.3390/nu13020395
- Pratama S, Lauren BC, Wisnu W. The efficacy of vitamin B12 supplementation for treating vitamin B12 deficiency and peripheral neuropathy in metformin-treated type 2 diabetes mellitus patients: a systematic review. Diabetes & Metabolic Syndrome. 2022;16(10):102634. doi:10.1016/j.dsx.2022.102634
- Bell DSH. Metformin-induced vitamin B12 deficiency can cause or worsen distal symmetrical, autonomic and cardiac neuropathy in the patient with diabetes. Diabetes, Obesity & Metabolism. 2022;24(8):1423–1428. doi:10.1111/dom.14734
- Kakarlapudi Y, Kondabolu SK, Tehseen Z, et al. Effect of metformin on vitamin B12 deficiency in patients with type 2 diabetes mellitus and factors associated with it: a meta-analysis. Cureus. 2022;14(12):e32277. doi:10.7759/cureus.32277
- Yazidi M, Kammoun E, Oueslati I, Chihaoui M. Metformin-induced vitamin B12 deficiency in patients with type 2 diabetes: a narrative review with a practical approach for screening, diagnosing, and managing vitamin B12 deficiency. Korean Journal of Family Medicine. 2024;45(4):189–198. doi:10.4082/kjfm.24.0090
- Infante M, Leoni M, Caprio M, Fabbri A. Long-term metformin therapy and vitamin B12 deficiency: an association to bear in mind. World Journal of Diabetes. 2021;12(7):916–931. doi:10.4239/wjd.v12.i7.916
Comments
